LGALS3 and non-small cell lung carcinoma: Furthermore, more recently, a new clinical trial has been opened to test the safety and efficacy of other Gal‐3 inhibitor (GB12211) in combination with atezolizumab in patients with advanced NSCLC (NTC05240131) remarking the relevance of including Gal‐3 as predictive biomarker for ICBs.